<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cantargia Ab — News on 6ix</title>
<link>https://6ix.com/company/cantargia-ab-1</link>
<description>Latest news and press releases for Cantargia Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 21 May 2026 14:35:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cantargia-ab-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d564f7beedb30cb6f80a0c.webp</url>
<title>Cantargia Ab</title>
<link>https://6ix.com/company/cantargia-ab-1</link>
</image>
<item>
<title>Bulletin from the Annual General Meeting in Cantargia AB (publ)</title>
<link>https://6ix.com/company/cantargia-ab-1/news/bulletin-from-the-annual-general-meeting-in-cantargia-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/bulletin-from-the-annual-general-meeting-in-cantargia-ab-publ</guid>
<pubDate>Thu, 21 May 2026 14:35:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following: To adopt the income statement and balance sheet as well as to allocate ...</description>
</item>
<item>
<title>Cantargia Publishes Interim Report for The First Quarter of 2026</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-interim-report-for-the-first-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-interim-report-for-the-first-quarter-of-2026</guid>
<pubDate>Tue, 19 May 2026 05:25:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026. "The first quarter of 2026 reflects both strong execution and important strategic progress for ...</description>
</item>
<item>
<title>Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-announces-early-results-from-trial-of-nadunolimab-in-mds-and-aml-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-announces-early-results-from-trial-of-nadunolimab-in-mds-and-aml-1</guid>
<pubDate>Mon, 27 Apr 2026 05:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early results from the ongoing Phase 1b/2a clinical ...</description>
</item>
<item>
<title>Notice of Annual General Meeting in Cantargia AB (publ)</title>
<link>https://6ix.com/company/cantargia-ab-1/news/notice-of-annual-general-meeting-in-cantargia-ab-publ-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/notice-of-annual-general-meeting-in-cantargia-ab-publ-1</guid>
<pubDate>Fri, 17 Apr 2026 05:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, ...</description>
</item>
<item>
<title>Cantargia Publishes Annual Report 2025</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-annual-report-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-annual-report-2025-1</guid>
<pubDate>Fri, 17 Apr 2026 05:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press release and is available on the company's website, ...</description>
</item>
<item>
<title>Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-at-van-lanschot-kempens-life-sciences-conference-2</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-at-van-lanschot-kempens-life-sciences-conference-2</guid>
<pubDate>Thu, 05 Mar 2026 09:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 5, 2026 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings at the Van Lanschot Kempen Life Sciences Conference ...</description>
</item>
<item>
<title>Cantargia to Participate in TD Cowen's Annual Healthcare Conference</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-in-td-cowens-annual-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-in-td-cowens-annual-healthcare-conference-1</guid>
<pubDate>Mon, 23 Feb 2026 08:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 23, 2026 /Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings at TD Cowen's 46th Annual Health Care Conference, ...</description>
</item>
<item>
<title>Cantargia Publishes Full Year Report 2025</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-full-year-report-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-full-year-report-2025-1</guid>
<pubDate>Fri, 20 Feb 2026 06:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. "Cantargia ...</description>
</item>
<item>
<title>Invitation to the Presentation of Cantargia's Annual Results for 2025</title>
<link>https://6ix.com/company/cantargia-ab-1/news/invitation-to-the-presentation-of-cantargias-annual-results-for-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/invitation-to-the-presentation-of-cantargias-annual-results-for-2025-1</guid>
<pubDate>Fri, 06 Feb 2026 10:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET. In conjunction to the report, investors, analysts, ...</description>
</item>
<item>
<title>Cantargia to Participate at Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-at-leerink-partners-global-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-at-leerink-partners-global-healthcare-conference-1</guid>
<pubDate>Wed, 28 Jan 2026 09:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / January 28, 2026 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings at the Leerink Partners Global Healthcare ...</description>
</item>
<item>
<title>Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-reports-first-patient-dosed-in-new-us-investigator-initiated-colorectal-cancer-study-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-reports-first-patient-dosed-in-new-us-investigator-initiated-colorectal-cancer-study-1</guid>
<pubDate>Fri, 23 Jan 2026 06:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination with checkpoint inhibitor therapy in up to ...</description>
</item>
<item>
<title>Cantargia Provides Update on Overall Survival Data from TRIFOUR</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-provides-update-on-overall-survival-data-from-trifour-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-provides-update-on-overall-survival-data-from-trifour-1</guid>
<pubDate>Fri, 05 Dec 2025 06:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study evaluating nadunolimab in triple-negative breast ...</description>
</item>
<item>
<title>Cantargia Publishes Interim Report for January to September 2025</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-interim-report-for-january-to-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-publishes-interim-report-for-january-to-september-2025-1</guid>
<pubDate>Wed, 19 Nov 2025 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the company's web page www.cantargia.com/en/investors/financial-reports ...</description>
</item>
<item>
<title>Cantargia Presents Nomination Committee Ahead of 2026 AGM</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-presents-nomination-committee-ahead-of-2026-agm-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-presents-nomination-committee-ahead-of-2026-agm-1</guid>
<pubDate>Wed, 12 Nov 2025 08:00:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed ahead of the 2026 Annual General Meeting (AGM). ...</description>
</item>
<item>
<title>Invitation to the Presentation of Cantargia's Interim Report January-September 2025</title>
<link>https://6ix.com/company/cantargia-ab-1/news/invitation-to-the-presentation-of-cantargias-interim-report-january-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/invitation-to-the-presentation-of-cantargias-interim-report-january-september-2025-1</guid>
<pubDate>Wed, 05 Nov 2025 08:45:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday, November 19, 2025, at 07:00 a.m. CET. In ...</description>
</item>
<item>
<title>Cantargia to Participate in Upcoming Conferences</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-in-upcoming-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-to-participate-in-upcoming-conferences-1</guid>
<pubDate>Thu, 23 Oct 2025 11:45:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences. Stifel 2025 Healthcare Conference, New York City Presentation ...</description>
</item>
<item>
<title>Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-appoints-dr-wolfram-dempke-as-chief-medical-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-appoints-dr-wolfram-dempke-as-chief-medical-officer-1</guid>
<pubDate>Thu, 02 Oct 2025 05:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical Officer, effective immediately. "We are delighted ...</description>
</item>
<item>
<title>Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-presents-data-at-an-aacr-conference-strengthening-il1rap-as-a-targetable-hallmark-in-pdac-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-presents-data-at-an-aacr-conference-strengthening-il1rap-as-a-targetable-hallmark-in-pdac-1</guid>
<pubDate>Tue, 30 Sep 2025 22:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA) High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this patient group has the longest survival when treated ...</description>
</item>
<item>
<title>Cantargia Closes the Acquisition of CAN10 by Otsuka</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-closes-the-acquisition-of-can10-by-otsuka-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-closes-the-acquisition-of-can10-by-otsuka-1</guid>
<pubDate>Thu, 11 Sep 2025 05:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's acquisition of the anti-IL1RAP antibody program ...</description>
</item>
<item>
<title>Cantargia Granted Important US Patent for Nadunolimab</title>
<link>https://6ix.com/company/cantargia-ab-1/news/cantargia-granted-important-us-patent-for-nadunolimab-1</link>
<guid isPermaLink="true">https://6ix.com/company/cantargia-ab-1/news/cantargia-granted-important-us-patent-for-nadunolimab-1</guid>
<pubDate>Wed, 27 Aug 2025 05:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent application 17/551,908 directed to the antibody ...</description>
</item>
</channel>
</rss>